CCCC
Income statement / Annual
Last year (2023), C4 Therapeutics, Inc.'s total revenue was $20.76 M,
a decrease of 33.25% from the previous year.
In 2023, C4 Therapeutics, Inc.'s net income was -$132.49 M.
See C4 Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$20.76 M
|
$31.10 M
|
$45.79 M
|
$33.20 M
|
$21.38 M
|
$19.36 M
|
| Cost of Revenue |
$117.71 M |
$7.57 M |
$2.91 M |
$77.47 M |
$47.66 M |
$28.59 M |
| Gross Profit |
-$96.95 M |
$23.52 M |
$42.88 M |
-$44.27 M |
-$26.28 M |
-$9.23 M |
| Gross Profit Ratio |
-4.67 |
0.76 |
0.94 |
-1.33 |
-1.23 |
-0.48 |
| Research and Development
Expenses |
$117.71 M
|
$117.84 M
|
$94.67 M
|
$78.44 M
|
$48.06 M
|
$28.59 M
|
| General & Administrative
Expenses |
$42.08 M
|
$42.79 M
|
$33.25 M
|
$15.20 M
|
$8.77 M
|
$7.16 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$42.08 M
|
$42.79 M
|
$33.25 M
|
$15.20 M
|
$8.77 M
|
$7.16 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$325,000.00 |
-$7,000.00 |
| Operating Expenses |
$159.79 M |
$160.63 M |
$127.92 M |
$93.64 M |
$56.83 M |
$35.75 M |
| Cost And Expenses |
$159.79 M |
$160.63 M |
$127.92 M |
$93.64 M |
$56.83 M |
$35.75 M |
| Interest Income |
$9.81 M |
$3.58 M |
$387,000.00 |
$393,000.00 |
$1.83 M |
$685,000.00 |
| Interest Expense |
$1.37 M |
$2.22 M |
$2.15 M |
$1.23 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$7.74 M
|
$7.57 M
|
$2.91 M
|
$2.84 M
|
$2.74 M
|
$3.57 M
|
| EBITDA |
-$122.10 M
|
-$124.28 M
|
-$78.84 M
|
-$62.89 M
|
-$30.56 M
|
-$15.12 M
|
| EBITDA Ratio |
-5.88 |
-4.05 |
-1.75 |
-1.76 |
-1.58 |
-0.78 |
| Operating Income Ratio
|
-6.7
|
-4.17
|
-1.79
|
-1.82
|
-1.66
|
-0.85
|
| Total Other
Income/Expenses Net |
$7.82 M
|
$1.36 M
|
-$1.76 M
|
-$6.51 M
|
$2.16 M
|
$678,000.00
|
| Income Before Tax |
-$131.21 M |
-$128.18 M |
-$83.89 M |
-$66.96 M |
-$33.30 M |
-$15.71 M |
| Income Before Tax Ratio
|
-6.32
|
-4.12
|
-1.83
|
-2.02
|
-1.56
|
-0.81
|
| Income Tax Expense |
$1.28 M |
-$1.68 M |
$2.15 M |
-$626,000.00 |
$804,000.00 |
$678,000.00 |
| Net Income |
-$132.49 M |
-$126.50 M |
-$86.04 M |
-$66.34 M |
-$34.10 M |
-$15.71 M |
| Net Income Ratio |
-6.38 |
-4.07 |
-1.88 |
-2 |
-1.59 |
-0.81 |
| EPS |
-2.67 |
-2.59 |
-1.87 |
-1.54 |
-0.79 |
-1.06 |
| EPS Diluted |
-2.67 |
-2.59 |
-1.87 |
-1.54 |
-0.79 |
-1.06 |
| Weighted Average Shares
Out |
$49.64 M
|
$48.86 M
|
$46.04 M
|
$43.06 M
|
$42.99 M
|
$14.79 M
|
| Weighted Average Shares
Out Diluted |
$49.64 M
|
$48.86 M
|
$46.04 M
|
$43.06 M
|
$42.99 M
|
$42.09 M
|
| Link |
|
|
|
|
|
|
